GlaxoSmithKline ( GSK ) recently announced that it has initiated a phase III study to evaluate the use of Benlysta (belimumab) in patients suffering from anti-neutrophil cytoplasmic antibodies (ANCA) positive vasculitis.
The multi-centre, randomized, double-blind phase III study will assess the efficacy and safety profile of Benlysta in combination with azathioprine as a maintenance therapy in ANCA positive vasculitis patients.
{iframe}http://www.nasdaq.com/article/glaxo-eyes-benlysta-label-expansion-analyst-blog-cm234242#.UWKvmas4Xbs{/iframe}